Skip to content
synovial sarcoma foundation
  • About
    • Mission
    • Initiatives
    • Affiliations
    • Leadership
    • Board of Directors
    • Careers
  • Resources
    • Synovial Sarcoma FAQ
    • Treatments
    • Clinical Trials & Therapies
    • Synovial Sarcoma Patient Survey
    • Synovial Sarcoma Tumor Board
    • Patient Stories
    • Patient Resources
    • Eddie’s Story
  • Research Programs
    • Clinical Research
    • Tumor Glow
    • Synovial Sarcoma Registry
  • Latest News
Donate

Send us a note

Please fill out the form below and we will gladly respond as soon as possible.

    Healthcare, Education

    Monophasic Synovial Sarcoma of the Posterior Pharyngeal Wall: A Rare Case Study

    January 26, 2026 ayushis Comments Off on Monophasic Synovial Sarcoma of the Posterior Pharyngeal Wall: A Rare Case Study
    Three people in medical attire are standing and talking in a brightly lit hallway. The image is blurred, and there is an exclamation mark inside a triangle warning icon overlayed in the center.
    Content Warning:
    This article references a published medical case study that includes graphic surgical images involving the head and neck region. While the information may be valuable and informative, some readers may find the images difficult to view. Please proceed with care.

    Synovial sarcoma most often develops in the extremities, but in rare cases, it can arise in the head and neck region. A published case study in the European Archives of Oto-Rhino-Laryngology highlights one such rare presentation: monophasic synovial sarcoma originating in the posterior pharyngeal wall.

    Although uncommon, head and neck synovial sarcoma presents unique diagnostic and treatment challenges due to the complexity of surrounding anatomy and the critical functions involved in breathing, swallowing, and speech. Studies like this one provide valuable insight for clinicians and patients navigating these rare diagnoses.

    A rare and challenging diagnosis

    In this case, a 25-year-old patient presented with symptoms including difficulty breathing while lying down, snoring, and trouble swallowing solid foods. Initial imaging and biopsy suggested a benign tumor, a situation that is not uncommon with synovial sarcoma due to its tendency to appear well-defined and non-aggressive on early scans.

    As symptoms progressed, further imaging and pathology revealed the diagnosis of monophasic synovial sarcoma of the posterior pharyngeal wall. This highlights a known challenge with synovial sarcoma: it can closely mimic benign conditions, leading to delays in diagnosis, particularly in rare anatomical locations like the head and neck.

    Imaging and pathology findings

    Advanced imaging showed a heterogeneous mass with areas of calcification—an imaging feature seen in a subset of synovial sarcoma cases. Definitive diagnosis was confirmed through histopathology, immunohistochemistry, and cytogenetic testing, which identified the characteristic t(X;18) chromosomal translocation associated with synovial sarcoma.

    The tumor was classified as monophasic, meaning it consisted primarily of spindle-shaped cells, a subtype that is frequently misdiagnosed due to its resemblance to other soft tissue tumors.

    Surgical treatment and reconstruction

    The primary treatment approach was wide surgical excision aimed at achieving clear margins. Due to the tumor’s size and location, the surgery required complex access and reconstruction. The surgical team used a lateral trapezius flap—a less commonly used reconstructive technique—to repair the defect created after tumor removal.

    This reconstructive approach allowed restoration of the pharyngeal wall while preserving critical structures involved in swallowing and airway protection. The study highlights this technique as a potential option for large defects in similar cases.

    Role of additional therapies

    Following surgery, the patient received radiation therapy. Chemotherapy was initiated but discontinued after one cycle due to side effects. At follow-up, the patient showed no evidence of disease and was able to resume oral intake with supportive therapy.

    While the role of chemotherapy in head and neck synovial sarcoma remains debated, studies suggest that a multidisciplinary approach—including surgery, radiation, and careful long-term surveillance—offers the best chance for disease control.

    Why this study matters

    Although this case represents a single patient, it adds to a limited body of knowledge about synovial sarcoma in the head and neck region. For patients and families affected by synovial sarcoma outside of the extremities, studies like this help improve understanding of how the disease can present, how it is diagnosed, and what treatment options may look like.

    Importantly, it also reinforces the value of second opinions, specialized pathology review, and care at centers experienced with sarcoma—especially when symptoms persist despite reassurance that a mass may be benign.

    Looking ahead

    Head and neck synovial sarcoma remains rare, but continued documentation and study are essential to improving diagnosis, treatment strategies, and long-term outcomes. Research like this contributes to ongoing efforts to refine surgical techniques, explore reconstruction options, and better understand the biology of this complex disease.

    For patients navigating synovial sarcoma of the head and neck, awareness and advocacy remain critical tools—both for timely diagnosis and access to specialized care.

    Content Warning:
    This article references a published medical case study that includes graphic surgical images involving the head and neck region. While the information may be valuable and informative, some readers may find the images difficult to view. Please proceed with care. Original study here.

    For more detailed information about Synovial Sarcoma resources and support, please visit our website.

    ayushis

    Post navigation

    Previous
    Next

    Search

    Categories

    • Black Flag Racing (2)
    • Children (1)
    • CHOP (3)
    • Development (9)
    • Dr. Theodore Laetsch (3)
    • Education (16)
    • Healthcare (9)
    • Latest News (8)
    • Programs (1)
    • Rare Cancer (5)
    • Rare Cancer Funding (1)
    • Research (17)
    • Synovial Sarcoma Conference (2)
    • Synovial Sarcoma Registry (3)
    • Teresa Belluco (1)
    • Tumor Board (2)

    Recent posts

    • A person wearing protective goggles, face mask, and gloves examines two small glass vials containing yellow and orange liquids in a laboratory setting.
      Synovial Sarcoma Research and Rare Cancer Drug Development: Challenges and Progress
    • A scientist wearing safety goggles and gloves examines samples through a microscope in a bright laboratory, with other researchers working in the background.
      New Research Identifies 4 Subtypes of Synovial Sarcoma, Opening Doors for Personalized Treatment
    • A scientist in a lab coat and gloves uses a pipette to add liquid to a test tube. Several test tubes filled with blue liquid are in a rack beside a microscope on a bright laboratory desk.
      What a Breakthrough in Ewing Sarcoma Means for Synovial Sarcoma

    Tags

    Afami-cel biomarker testing synovial sarcoma BRAF mutated synovial sarcoma cancer innovation CHOP clinical trial clinical trials rare cancer immunotherapy new treatments for synovial sarcoma nonprofit drug development pediatric synovial sarcoma Rare Cancer rare cancer clinical trials rare cancer research rare disease drug development rare disease funding rare pediatric cancer rare soft tissue sarcoma research soft tissue cancer soft tissue sarcoma solitary fibrous tumor SS18-SSX fusion SS18-SSX translocation SS18::SSX SS research STAT6 marker SFT Synovial Sarcoma synovial sarcoma case report synovial sarcoma clinical trials synovial sarcoma diagnosis Synovial Sarcoma Foundation synovial sarcoma in children synovial sarcoma research synovial sarcoma subtypes synovial sarcoma symptoms synovial sarcoma treatment synovial sarcoma treatment market targeted cancer therapy targeted therapies for sarcoma targeted therapy TECELRA Tecelra T-cell therapy trabectedin webinar

    Related posts

    A person wearing protective goggles, face mask, and gloves examines two small glass vials containing yellow and orange liquids in a laboratory setting.
    Rare Cancer, Development

    Synovial Sarcoma Research and Rare Cancer Drug Development: Challenges and Progress

    April 27, 2026 ayushis Comments Off on Synovial Sarcoma Research and Rare Cancer Drug Development: Challenges and Progress

    Developing treatments for rare cancers like synovial sarcoma remains one of the biggest challenges in modern medicine—but recent progress shows what’s possible. One major milestone came with the FDA approval of Tecelra, the first engineered T-cell therapy approved for a solid tumor in the U.S., including synovial sarcoma. Why Rare Cancers Face Unique Challenges Synovial […]

    A scientist wearing safety goggles and gloves examines samples through a microscope in a bright laboratory, with other researchers working in the background.
    Education, Healthcare

    New Research Identifies 4 Subtypes of Synovial Sarcoma, Opening Doors for Personalized Treatment

    April 23, 2026 ayushis Comments Off on New Research Identifies 4 Subtypes of Synovial Sarcoma, Opening Doors for Personalized Treatment

    Synovial sarcoma is a rare and aggressive soft tissue cancer, but new research is helping us better understand how it behaves—and how it may be treated in the future. A recent study using advanced single-cell RNA sequencing has identified four distinct subtypes of synovial sarcoma, each with unique biological features and potential treatment pathways. Why […]

    A scientist in a lab coat and gloves uses a pipette to add liquid to a test tube. Several test tubes filled with blue liquid are in a rack beside a microscope on a bright laboratory desk.
    Development, Education

    What a Breakthrough in Ewing Sarcoma Means for Synovial Sarcoma

    April 21, 2026 ayushis Comments Off on What a Breakthrough in Ewing Sarcoma Means for Synovial Sarcoma

    A new Phase 1/2 trial in Ewing sarcoma, just profiled in Clinical Trial Vanguard and published in Nature Medicine, delivered the kind of result the synovial sarcoma community should be watching closely. The trial paired trabectedin with low-dose irinotecan to target the EWS::FLI1 fusion, the oncogenic driver of Ewing sarcoma. For more than a decade, […]

    The Synovial Sarcoma Foundation is a registered 501(c)(3) nonprofit organization. Tax ID number is 33-4027591. Contributions to the Synovial Sarcoma Foundation are tax-deductible to the extent permitted by law.

    • Terms & conditions
    • Privacy policy
    synovial sarcoma foundation
    • community@synovialsarcoma.org
    1025 Thomas Jefferson St. NW, Suite W-3200, Washington DC 20007
    Facebook-f X-twitter Linkedin

    Navigation

    • About
    • Research Programs
    • Patient Stories
    • Resources

    Stay in touch